Recombinant protein therapeutics - success rates, market trends and values to 2010
Article Abstract:
The success rates and market trends in recombinant deoxyribo nucleic acid (rDNA) protein for the period 2004 to 2010 are studied. It is seen that the recombinant protein sector is expected to drive the growth of medical biotechnology over the coming years and the rDNA therapeutics market's value could grow from $34,807m in 2004 to $41,744m in 2006 and then to $52,150m in 2010.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Monoclonal antibodies in the clinic
Article Abstract:
Early on, monoclonal antibodies (mAbs) were touted as being able to cure many diseases. Recent clinical trials have shown that improved strains of mAbs are indeed effective. Ten mAbs have been approved by the FDA, and 70 are in clinical trials.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Tune up those rock pitches. George Polk Awards names top stories for 2005. 'Give us an expert', financial editors say
- Abstracts: Interdependencies between marketing and public relations disciplines as correlates of communication organisation
- Abstracts: Product attribute-based voter segmentation and resource advantage theory. part 2 Political parties, the internet and the 2005 General Election: from web presence to e-campaigning?
- Abstracts: Forward/up directional incompatibilities during cursor placement within graphical user interfaces. Characteristics of cursor trajectories controlled by the computer mouse
- Abstracts: The effect of audit committee shareholding, financial expertise and size of interim financial disclosures. The distribution of earnings relative to targets in the European Union